Articles tagged with Glioblastomas
A personalized vaccine has been shown to be safe and effective in treating glioblastoma, a fast-growing brain cancer. The vaccine elicited robust and broad immune responses that appeared to increase recurrence-free survival in patients after surgery.
Glioblastoma is a highly aggressive brain tumor that has seen modest improvements in survival rates over the past decade. Researchers at UCLA's Jonsson Comprehensive Cancer Center are part of a national effort to develop more personalized approaches to care, combining advanced imaging and analysis of tumor tissue samples and blood test...
A NIH-funded study discovered that testosterone may play a key role in limiting brain tumor growth in men by suppressing inflammation and stress hormone production. Analysis of over 1,300 men with glioblastoma found that supplemental testosterone was significantly associated with improved survival rates.
Dr. Aparna Bhaduri receives $750k Pershing Square Sohn Cancer Prize for her innovative glioblastoma research. Her advanced human organoid models reveal how tumors interact with the immune system and brain cells, driving tumor aggressiveness.
Hyperbaric oxygen therapy (HBOT) exhibits dual effects in glioblastoma management, enhancing radiosensitivity and chemotherapy efficacy while promoting tumor progression. HBOT normalizes the tumor microenvironment via vessel normalization and immune cell modulation, attenuating cancer stem cell properties.
Researchers at DZNE discovered complex, situation-dependent interactions between glioblastoma cells and microglia in the brain. The study found that microglial activity changes as tumors spread, influencing containment and spread of the disease.
Researchers discovered a powerful molecule called miR-181d that weaks tumors and helps the immune system fight back against glioblastoma. The study found that tumors in 'exceptional responders' contain higher levels of miR-181d, which blocks cancer cells' ability to repair DNA damage.
Researchers discovered that neuronal nitric oxide synthase drives neuroblastoma through the mTOR signaling cascade. Treating cancer cells with a selective inhibitor called BA-101 collapsed tumor growth in mice with striking force, and silencing the nNOS gene also led to significant results.
Researchers at Mayo Clinic have developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, improving survival rates in preclinical models of glioblastoma. The approach uses small lipid-based particles to target tumor cells and enhance the impact of radiation therapy.
Researchers at Adelaide University identified CD47 as a critical mechanism driving glioblastoma growth and spread. The study found that removing or blocking CD47 reduced tumour cell proliferation, migration, and invasion, leading to improved survival times in animal models.
Recent discoveries have shed light on gene expression control in tumor growth, revealing the critical role of epigenetic marks and genomic imprinting. The findings have significant implications for cancer treatment, as they suggest that disrupting the tumor's access to neural signaling may halt its growth.
Blocking two key 'don't eat me signals' in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in glioblastoma models. Researchers found that simultaneously blocking CD47 and CD24 improved immunotherapy response, allowing macrophages to better recognize and attack cancer cells.
Researchers developed magnetically controlled microrobots made from diatoms to target glioblastoma lesions with photodynamic therapy. The microrobots achieved a significant cytotoxic effect on primary glioblastoma cells and demonstrated good biocompatibility.
The novel approach outperforms standard CAR-T cell therapy in preclinical studies using mouse models of glioblastoma and ovarian cancer. Armored CAR-T cells eliminate tumors, reshape the tumor environment, and boost immune-cell activity.
Approximately 40 cancer patients will receive LMP744 for five consecutive days, with biological analyses conducted on brain tissues before and after treatment. If results are favorable, treatment will continue for 12 cycles to evaluate parameters such as progression-free survival and overall survival.
PhD candidate Michael Gomes is developing advanced nanoscale drug carriers to deliver chemotherapy more effectively to brain tumours. His research focuses on polydopamine nanoparticles and the glymphatic system to reach tumours directly, potentially increasing drug concentrations and reducing toxic effects.
A single injection of an oncolytic virus recruits immune cells to penetrate and persist deep within brain tumors, inducing long-term infiltration of immune T cells. This therapy expands pre-existing T cells in the brain, leading to a therapeutic benefit for patients with glioblastoma.
Researchers identified a previously unrecognized metabolic defence mechanism in aggressive brain tumours: a sugar-rich shield that protects tumour cells from ferroptosis. The study found that the sugar shield and lipid droplet storage mechanisms cooperate to evade cell death.
Researchers have identified three unique subtypes of mismatch repair deficient high-grade gliomas, providing a clearer understanding of their development and behavior. The findings are helping guide more precise therapies and offer hope for a potential vaccine to target cancer cells earlier.
A UCalgary study found that adding high doses of vitamin B3 to the treatment plan may help rejuvenate compromised immune cells to kill tumour cells. The clinical trial showed promising results, with 82% of participants free of cancer progression at six-months.
Researchers identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus. The study found that adding an immune booster increased survival times and improved immunological fitness.
Researchers at the University of Virginia Health System have identified a molecule that blocks the gene responsible for glioblastoma, a fast-growing and deadly brain cancer. The compound shows promise in preventing the invasive cancer from spreading through the brain without causing harm to healthy tissue.
Researchers at the University of Cincinnati Cancer Center are developing a new treatment for glioblastoma, a highly aggressive brain cancer. The team is using 'glioblastoma-on-a-chip' technology and wafer delivery to stimulate the immune system and improve patient outcomes.
Researchers developed miniature 3D tumor organoid models that closely mimic the human brain, revealing how glioblastoma interacts with surrounding brain cells and immune system. The models identified PTPRZ1 as a key regulator of tumor behavior, which helps determine its aggressiveness.
Researchers review EMT mechanisms and its impact on GBM progression, highlighting key signaling pathways and GSCs. EMT-targeted therapies offer promising strategies to disrupt tumor growth and enhance immune responses.
Cancer cells tap into the nervous system's power grid by forming synaptic contacts with nerve cells, promoting tumor growth and spread. Venkataramani's research aims to repurpose the drug perampanel for glioblastoma treatment and develop gene therapy approaches to disconnect tumors from the nervous system.
Researchers developed a new method to identify effective treatment combinations for glioblastoma by analyzing individual cell types and their gene expression signatures. This approach has the potential to personalize cancer treatment and may be useful for other cancers and diseases.
Researchers developed a new diagnostic chip that can detect tumor cells in blood, allowing for real-time monitoring of brain cancer treatment effectiveness. The GlioExoChip uses extracellular vesicles to assess treatment response, providing a quick and minimally invasive way to inform doctors about chemotherapy efficacy.
Researchers discovered glioblastoma cells use PRDM9 to survive chemotherapy and regrow tumors. By blocking PRDM9 or cutting off cholesterol supply, persister cells can be wiped out, improving survival in mice. This breakthrough offers new strategies for treating the deadliest brain cancer.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
Christina Tringides' CHAMELEON project aims to develop soft, sensor-laden brain implants that can monitor and treat glioblastoma with greater precision. Her lab creates hydrogel-based arrays with conductive electrodes to track neural signals in real-time.
Researchers at Mass General Brigham developed a modified herpes simplex virus that stimulates the immune system to attack glioblastoma cells, increasing T-cell and natural killer cell responses. The virus, engineered to recognize markers found on glioblastoma cells, also increases overall survival in preclinical models.
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
A clinical trial found a nearly 40% increase in overall survival for glioblastoma patients treated with focused ultrasound and chemotherapy. The study also showed that liquid biopsy tests can detect cancer biomarkers, which are closely concordant with patient outcomes.
Researchers developed a noninvasive approach using nasal drops to deliver potent tumor-fighting medicine to the brain, boosting the immune response and eradicating glioblastoma tumors in mice. The nano-sized medicine successfully activated the STING pathway and armed the immune system to fight the cancer.
A team at the University of Pennsylvania has solved the mechanism of action of hydralazine, revealing its potential to halt the growth of brain cancer cells. By blocking an oxygen-sensing enzyme, hydralazine can reduce intracellular calcium levels, causing blood vessels to relax and tumor cells to enter a dormant state.
Research highlights the role of ATAD2 in promoting glioma progression by co-activating PDK1 with E2F1, leading to poorer prognoses in patients. A personalized prognostic nomogram using CTARS has been developed for predicting clinical outcomes.
Researchers have discovered that ATAD2 promotes glioma progression by working with E2F1 to activate PDK1. The study also found that high levels of ATAD2 are associated with poorer outcomes in glioma patients.
Researchers found that lower LRIG1 expression is linked to more aggressive gliomas, a type of brain tumor. The study suggests that LRIG1 could serve as a useful marker for tumor severity and potentially as a target for future therapies.
Glioblastoma's unique defenses hinder CAR-T cell efficacy due to antigenic heterogeneity and immunosuppressive tumor microenvironment. Novel strategies, including multi-target and logic-gated CARs, switchable and universal CARs, and combination therapies, aim to breach these barriers and reprogram the immune system.
Researchers developed a biodegradable implant that slowly releases drugs to myeloid cells, waking up the immune system to fight cancer. The approach prevented tumor recurrence in over half of mice and showed promising results in human samples.
Epithelial-mesenchymal transition (EMT) is a key driver of glioblastoma progression and therapy resistance. Emerging strategies to disrupt EMT signaling, such as natural compounds and small-molecule inhibitors, hold promise for reducing tumor invasion and enhancing sensitivity to standard therapies.
Researchers have developed a novel treatment approach using amplitude-modulated radiofrequency electromagnetic fields to slow glioblastoma cell growth and target tumor stem cells. The therapy shows promise in both laboratory experiments and clinical trials with two patients, demonstrating potential for treating brain cancer.
Researchers create novel antibody-based treatment that combines diagnostic and therapeutic capabilities to target LRRC15-expressing tumors, slowing growth and extending survival. The approach shows promise in preclinical models by priming tumors for immune response and boosting immunotherapy's effectiveness.
A multi-institutional study found that serially testing tumor samples can detect immune system activation in recurrent glioblastoma even when traditional imaging measures cannot. The researchers used multi-omic analysis and integrated data from various sources to show positive changes in the tumor microenvironment over time.
The proton therapy cohort of NRG-BN001 demonstrated improved overall survival (OS) for patients with newly diagnosed glioblastoma, with a 6.8% absolute survival advantage at 2 years. The results support the development of a phase III randomized trial to confirm these findings.
A new study decodes the mechanism of glioblastoma's resistance to chemotherapy by identifying a HIF-independent circuit built around the epigenetic enzyme PRMT2. Researchers found that combining an existing orphan drug with standard chemotherapy can overcome this resistance, doubling survival without added toxicity.
Researchers identified Wnt7b as a determinant of resistance to immune checkpoint blockers in glioblastoma and developed a combination therapy with WNT974 that sensitizes GBM to anti-PD1 therapy, improving anti-tumor immunity. This approach offers a promising new therapeutic avenue for glioblastoma patients.
Virginia Tech researchers create method combining MRI, fluid dynamics, and algorithm to identify hidden glioblastoma cells. The technique uses fluid flow patterns to predict tumor re-growth, allowing for more aggressive surgical approaches. This technology has potential to improve cancer treatment outcomes
A team of scientists has identified rogue DNA rings as early drivers of glioblastoma growth, suggesting a window of opportunity for earlier detection and treatment. The study suggests that targeting these DNA rings could lead to more effective treatments.
Scientists have found a way to stop brain cancer cells from spreading by 'freezing' hyaluronic acid molecules in place. This approach could lead to a new type of treatment for glioblastoma, the most aggressive form of brain cancer.
Researchers from the University of Maryland School of Medicine have developed a reliable measurement for opening the blood-brain barrier using focused ultrasound. By analyzing acoustic emissions signals generated by circulating microbubbles, they found that this method can predict blood-brain barrier opening in patients with glioblasto...
The Ellen Siow Professorship aims to advance education and research in neuro-oncology, specifically glioblastoma. This will drive the development of innovative programmes and interventions, fostering progress that benefits people in Singapore and beyond.
Researchers at UCL discovered that blocking brain damage triggered by glioblastomas can slow cancer growth and maintain normal brain function. The study found that early-stage tumours damaged axons, accelerating tumor growth, but deactivating SARM1 slowed tumor progression.
Researchers identify B-cell lymphoma 6 (BCL6) as a key player in promoting glioma cell proliferation and progression. A novel small-molecule inhibitor YK01 targets BCL6, showing potent anti-tumor effects in GBM cells and animal models.
The NRG-BN007 clinical trial found that combining ipilimumab and nivolumab with radiation therapy did not improve progression-free survival for patients with newly diagnosed MGMT-unmethylated glioblastoma. The treatment combination showed no significant difference in overall survival either.
Researchers are developing an AI imaging approach to distinguish between tumor progression and treatment effects in glioblastoma patients, promising to improve care and outcomes. The AI approach has already shown accuracy rates of up to 74% in initial testing.
Researchers at Fralin Biomedical Research Institute have identified a potential target for experimental drugs that block PRMT5, a naturally occurring enzyme some tumors rely on for survival. The study found a new drug combination that works against certain hard-to-treat cancers.
Researchers Sontheimer and Monje have made groundbreaking discoveries in brain tumor growth, revealing how nerve cells promote the development of aggressive gliomas. Their work has laid the foundation for new treatments and clinical trials, offering hope for innovative therapies.
Gene coexpression analysis reveals optimal markers of cell types and states, providing opportunities for developing novel biomarkers and targeted treatment strategies for glioma patients. Dr. Oldham's work tackles the reproducibility crisis in science, emphasizing data metadata standardization.